Latuda Lowest Starting Dose
The lowest starting dose of Latuda (lurasidone) is 20 mg once daily, which is specifically indicated for bipolar I depression in adults and pediatric patients (10-17 years), as well as for patients with moderate-to-severe renal or hepatic impairment. 1
Standard Starting Doses by Indication
For Bipolar I Depression
- Adults: 20 mg once daily (monotherapy or adjunctive with lithium/valproate) 1
- Pediatric patients (10-17 years): 20 mg once daily as monotherapy 1
- No initial titration required
- Can increase after one week based on clinical response in pediatric patients
For Schizophrenia
- Adults: 40 mg once daily 1
- Adolescents (13-17 years): 40 mg once daily 1
- No initial titration required
Special Populations Requiring 20 mg Starting Dose
Renal Impairment: Patients with moderate (CrCl 30-<50 mL/min) or severe (CrCl <30 mL/min) renal impairment must start at 20 mg daily, with a maximum dose not exceeding 80 mg/day 1
Hepatic Impairment: Patients with moderate (Child-Pugh 7-9) or severe (Child-Pugh 10-15) hepatic impairment must start at 20 mg daily. Maximum doses are 80 mg/day for moderate impairment and 40 mg/day for severe impairment 1
Drug Interactions: When co-prescribed with moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil), the starting dose should be 20 mg daily with a maximum of 80 mg/day 1
Critical Administration Requirements
Latuda must be taken with food (at least 350 calories) to ensure adequate absorption. Administration with food increases bioavailability approximately 2-fold (AUC) and 3-fold (Cmax) 1. This is not optional—the clinical trials demonstrating efficacy were conducted with food administration.
Real-World Dosing Patterns
In clinical practice, the majority of bipolar depression patients (67%) ultimately receive 20-40 mg daily 1, 2. A retrospective claims analysis found that 90% of patients initiated lurasidone at either 40 mg or 80 mg daily (mean 51.9 mg/day), with only 7.1% starting at 20 mg 2. However, this reflects schizophrenia dosing patterns more than bipolar depression, where 20 mg is the FDA-recommended starting dose.
Dose-Response Evidence
Recent meta-analysis data indicate that 40-60 mg daily represents the optimal therapeutic dose range for bipolar depression, balancing efficacy with tolerability 3. At 50 mg daily, lurasidone showed significant improvements in depression (SMD -0.60), anxiety (SMD -0.32), and clinical global impression (SMD -0.67) 3. Side effects increased with higher doses, while metabolic effects remained minimal at doses below 60 mg 3.
Clinical Decision Algorithm
Start at 20 mg daily if:
- Treating bipolar I depression (any age)
- Patient has renal impairment (moderate or severe)
- Patient has hepatic impairment (moderate or severe)
- Patient is taking moderate CYP3A4 inhibitors
- Patient is elderly or frail
- Concern for akathisia or extrapyramidal symptoms
Start at 40 mg daily if:
- Treating schizophrenia in adults or adolescents ≥13 years
- No organ dysfunction or drug interactions present
- Need for more rapid symptom control
Important Caveats
Avoid grapefruit and grapefruit juice, as these inhibit CYP3A4 and can significantly increase lurasidone levels 1
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (rifampin, carbamazepine, St. John's wort, phenytoin) are contraindicated with lurasidone 1
The most common side effects at therapeutic doses include nausea, akathisia, somnolence, and headache 4, 5. These are generally dose-dependent, supporting the use of the lowest effective dose.